Quarterly ResultMay 7, 2026, 04:41 PM
IN8bio Q1 Net Loss $5.1M; Going Concern Doubt Raised
AI Summary
IN8bio, Inc. reported a net loss of $5.1 million for the first quarter of 2026, a slight improvement from $5.6 million in the prior year's quarter. The company's cash balance declined to $21.9 million as of March 31, 2026, leading to a disclosure of substantial doubt about its ability to continue as a going concern. Management plans to address this through pipeline prioritization, raising additional capital via equity/debt offerings, and strategic collaborations.
Key Highlights
- IN8bio reported a Q1 2026 net loss of $5.1 million, an improvement from $5.6 million in Q1 2025.
- Cash balance decreased to $21.9 million as of March 31, 2026, from $27.1 million at December 31, 2025.
- The company's accumulated deficit reached $146.2 million as of March 31, 2026.
- Operating expenses for Q1 2026 were $5.3 million, down from $5.7 million in Q1 2025.
- Net cash used in operating activities increased to $4.9 million in Q1 2026 from $3.1 million in Q1 2025.
- Substantial doubt about IN8bio's ability to continue as a going concern was raised.
- Potential additional proceeds of up to $29.1 million from warrant exercises and milestone payments.
- A one-for-thirty reverse stock split was effected in June 2025, retroactively applied to all periods.